Share on StockTwits

United Therapeutics (NASDAQ:UTHR) Director Christopher Causey unloaded 1,500 shares of United Therapeutics stock on the open market in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $96.48, for a total value of $144,720.00. Following the completion of the transaction, the director now directly owns 733 shares of the company’s stock, valued at approximately $70,720. The transaction was disclosed in a document filed with the SEC, which is available at this link.

United Therapeutics (NASDAQ:UTHR) traded up 0.29% on Thursday, hitting $96.98. 343,002 shares of the company’s stock traded hands. United Therapeutics has a 52-week low of $61.23 and a 52-week high of $116.65. The stock has a 50-day moving average of $99.24 and a 200-day moving average of $99.36. The company has a market cap of $4.672 billion and a P/E ratio of 21.01.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Tuesday, April 29th. The company reported $1.77 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.65 by $0.12. The company had revenue of $289.40 million for the quarter, compared to the consensus estimate of $300.14 million. During the same quarter in the prior year, the company posted $1.19 earnings per share. The company’s quarterly revenue was up 18.1% on a year-over-year basis. On average, analysts predict that United Therapeutics will post $7.77 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on UTHR shares. Analysts at Zacks reiterated a “neutral” rating on shares of United Therapeutics in a research note on Tuesday, May 27th. They now have a $104.00 price target on the stock. Finally, analysts at Standpoint Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 7th. They now have a $118.00 price target on the stock. Six analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $95.93.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.